Skip to main content

GH Research PLC

corporate_fare Company Profile

GH Research PLC

GHRS·NASDAQ·Life Sciences·CIK 0001855129

GH Research Ireland Limited is a clinical-stage biopharmaceutical company focused on developing treatments for depression. The company's primary objective is to transform patients' lives by creating a practice-changing treatment for depression, with an initial focus on treatment-resistant depression (TRD). Its portfolio includes two proprietary mebufotenin therapies: GH001, an inhalable product candidate, and GH002, an intravenous product candidate. While GH001 currently uses a third-party vaporization device, GH Research Ireland Limited is developing its own proprietary aerosol delivery device, which is undergoing clinical investigation in Europe. The company has completed two Phase 1 healthy volunteer clinical trials for GH001 (GH001-HV-101 and GH001-HV-103). These trials observed that GH001, when administered via inhalation, was well tolerated at the single dose levels investigated and within an individualized dosing regimen (IDR) involving intra-subject dose escalation within a single day. Since January 1, 2023, the company's principal expenditures have been research and development expenses. GH Research Ireland Limited was originally incorporated in Ireland on October 16, 2018, as GH Research Limited, and re-registered as GH Research Ireland Limited on March 29, 2021. Its principal place of business is in Dublin 2, D02 RY95, Ireland.

GH Research PLC (NASDAQ:GHRS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for GHRS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for GHRS spans 6-K, F-3, 424B5.

Recent high-impact activity:

  • GH Research Q3: FDA-Aligned Pivotal TRD Design, EoP2 Set for Q1 2027, $350.6M Cash
  • GH Research Q2 2026: $362.7M Cash Runway, FDA Phase 3 Alignment, and Key Patent Wins
  • GH Research Reports 100% Remission in Phase 2a Postpartum Depression Trial for GH001
  • GH001 Shows Strong Efficacy in Anhedonia, Anxiety, and Quality of Life, Independent of Prior Treatment Failures
  • GH Research Files $400M Universal Shelf Registration for Future Capital Raises

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$48.26M
Diluted EPS
-$0.79
Op. Cash Flow
-$43.55M
Free Cash Flow
-$43.67M
Operating Income
-$60.72M
Cash & Equivalents
$30.97M
Debt / Equity
0.00×
Shares Outstanding
62.03M sh
Source: 20-F · filed 2026-03-05 · accession 0001140361-26-007986

Short Interest & Short Volume

6.51 days to cover

FINRA reported short interest of 2,079,373 shares in GHRS as of the October 30, 2026 settlement, a 3.4% increase from the prior period — about 6.5 days to cover at its recent average daily volume. On November 19, 2026, 53.0% of GHRS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,079,373 shares as of October 30, 2026
Change vs prior period▲ 3.4%
Days to cover6.51 at avg daily volume of 319,406
Daily short volume (FINRA facilities)53.0% of 93,694 shares on November 19, 2026
5-day average short volume42.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

GHRS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with G →
$17.54 -5.50% today
52-week range · as of 2026-11-13 $12.04 – $31.44
Market cap
$1.2B
Volume
228.4K (0.7× avg)
3-mo avg 340.7K
Live data · 2026-11-20 20:50 UTC · Market open

show_chartPrice Chart

Loading chart...

feed GHRS - Latest Insights

GHRS
Nov 13, 2026, 8:22 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $18.87
Real-time Price: $17.54 info
Change: -$1.33 (-7%) info
Market Cap: $1.198B info
GHRS
Aug 06, 2026, 7:24 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $29.08
Real-time Price: $17.54 info
Change: -$11.54 (-40%) info
Market Cap: $1.198B info
GHRS
Jun 04, 2026, 8:35 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $24.56
Real-time Price: $17.54 info
Change: -$7.02 (-29%) info
Market Cap: $1.198B info
GHRS
May 21, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $22.35
Real-time Price: $17.54 info
Change: -$4.81 (-22%) info
Market Cap: $1.198B info
GHRS
May 14, 2026, 9:20 AM EDT
Filing Type: F-3
Importance Score:
8
Price at Filing: $21.57
Real-time Price: $17.54 info
Change: -$4.03 (-19%) info
Market Cap: $1.198B info
GHRS
May 14, 2026, 9:02 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $21.57
Real-time Price: $17.54 info
Change: -$4.03 (-19%) info
Market Cap: $1.198B info
GHRS
May 14, 2026, 7:21 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $22.34
Real-time Price: $17.54 info
Change: -$4.80 (-21%) info
Market Cap: $1.198B info
GHRS
Apr 29, 2026, 8:26 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $19.50
Real-time Price: $17.54 info
Change: -$1.96 (-10%) info
Market Cap: $1.198B info
GHRS
Apr 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $19.71
Real-time Price: $17.54 info
Change: -$2.17 (-11%) info
Market Cap: $1.198B info
GHRS
Apr 20, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $21.01
Real-time Price: $17.54 info
Change: -$3.47 (-17%) info
Market Cap: $1.198B info
GHRS
Mar 25, 2026, 11:10 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $13.96
Real-time Price: $17.54 info
Change: +$3.58 (+26%) info
Market Cap: $1.198B info
GHRS
Mar 05, 2026, 7:08 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $15.69
Real-time Price: $17.54 info
Change: +$1.85 (+12%) info
Market Cap: $1.198B info
GHRS
Mar 05, 2026, 7:04 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $15.69
Real-time Price: $17.54 info
Change: +$1.85 (+12%) info
Market Cap: $1.198B info
GHRS
Jan 15, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $16.48
Real-time Price: $17.54 info
Change: +$1.06 (+6%) info
Market Cap: $1.198B info
GHRS
Jan 13, 2026, 7:15 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $15.84
Real-time Price: $17.54 info
Change: +$1.70 (+11%) info
Market Cap: $1.198B info
GHRS
Jan 08, 2026, 7:30 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $17.82
Real-time Price: $17.54 info
Change: -$0.280 (-2%) info
Market Cap: $1.198B info
GHRS
Jan 05, 2026, 7:20 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $15.55
Real-time Price: $17.54 info
Change: +$1.99 (+13%) info
Market Cap: $1.198B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets